BRPI0519325A2 - compostos, complexo antibiàtico 107891, seus fatores a1 e a2, sais farmaceuticamente aceitÁveis, processo para produzir composiÇço e uso do mesmo - Google Patents
compostos, complexo antibiàtico 107891, seus fatores a1 e a2, sais farmaceuticamente aceitÁveis, processo para produzir composiÇço e uso do mesmoInfo
- Publication number
- BRPI0519325A2 BRPI0519325A2 BRPI0519325-7A BRPI0519325A BRPI0519325A2 BR PI0519325 A2 BRPI0519325 A2 BR PI0519325A2 BR PI0519325 A BRPI0519325 A BR PI0519325A BR PI0519325 A2 BRPI0519325 A2 BR PI0519325A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibiotic
- factors
- pharmaceutically acceptable
- acceptable salts
- compounds
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 3
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 108010062877 Bacteriocins Proteins 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 abstract 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract 1
- 241000906785 Microbispora sp. Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960003085 meticillin Drugs 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
COMPOSTOS, COMPLEXO ANTIBIàTICO 107891, SEUS FATORES A1 E A2, SAIS FARMACEUTICAMENTE ACEITAVEIS, PROCESSO PARA PRODUZIR COMPOSIÇçO E USO DO MESMO. A presente invenção refere-se a uma substância antibjótica de origem microbiana, arbitrariamente denominada antibiótico 107891, a qual é produzida por fermentação de Microbispora sp. ATCC PTA-5024, os seus sais farmaceuticamente aceitáveis e composições suas, e seu uso como um agente antibacteriano com atividade inibitória versus micróbios suscetíveis. Antibiótico 107891, o qual é um complexo compreendendo dois Fatores, denominados Fator A1 e A2, tem uma estrutura peptídica contendo lantionina e metil-lantionina como constituintes os quais são características típicas dos antibióticos do grupo dos lantibióticos. Antibiótico 107891 e seus Fatores A1 e A2 apresentam uma boa atividade antibacteriana contra bactérias Grampositivas, incluindo cepas resistentes a meticilina e resistentes a vancomicina, e é ativo também contra algumas bactérias Gram-negativas, tais como M. catharralis, espécies de Neisseria e H. influenzae e Mycobacteria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/035,296 US7319088B2 (en) | 2003-07-18 | 2005-01-12 | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
| PCT/US2005/004843 WO2006075988A1 (en) | 2005-01-12 | 2005-01-19 | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519325A2 true BRPI0519325A2 (pt) | 2009-01-13 |
Family
ID=39705004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519325-7A BRPI0519325A2 (pt) | 2005-01-12 | 2005-01-19 | compostos, complexo antibiàtico 107891, seus fatores a1 e a2, sais farmaceuticamente aceitÁveis, processo para produzir composiÇço e uso do mesmo |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1855705B1 (pt) |
| JP (1) | JP4189026B2 (pt) |
| CN (1) | CN101098707B (pt) |
| AU (1) | AU2005324536B2 (pt) |
| BR (1) | BRPI0519325A2 (pt) |
| CA (1) | CA2593818C (pt) |
| DK (1) | DK1855705T3 (pt) |
| EA (1) | EA012164B1 (pt) |
| ES (1) | ES2391085T3 (pt) |
| HR (1) | HRP20120809T1 (pt) |
| IL (1) | IL184376A0 (pt) |
| MX (1) | MX2007008512A (pt) |
| NO (1) | NO20073491L (pt) |
| NZ (1) | NZ556369A (pt) |
| PL (1) | PL1855705T3 (pt) |
| RS (1) | RS52513B (pt) |
| SI (1) | SI1855705T1 (pt) |
| TN (1) | TNSN07262A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7351687B2 (en) * | 2003-07-18 | 2008-04-01 | Vicuron Pharmaceuticals, Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
| KR20110086582A (ko) * | 2008-11-24 | 2011-07-28 | 센티넬라 파마세티컬즈, 인크. | 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218362B1 (en) * | 1997-09-08 | 2001-04-17 | Universite Laval | Lantibiotic from Streptococcus mutans and uses thereof |
| US6551591B1 (en) * | 2001-09-07 | 2003-04-22 | Essential Therapeutics, Inc. | Antibiotics from microbispora |
| ES2281808T3 (es) * | 2003-07-18 | 2007-10-01 | Vicuron Pharmaceuticals, Inc. | Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo. |
-
2005
- 2005-01-19 BR BRPI0519325-7A patent/BRPI0519325A2/pt not_active IP Right Cessation
- 2005-01-19 SI SI200531575T patent/SI1855705T1/sl unknown
- 2005-01-19 PL PL05723117T patent/PL1855705T3/pl unknown
- 2005-01-19 EP EP05723117A patent/EP1855705B1/en not_active Expired - Lifetime
- 2005-01-19 CA CA2593818A patent/CA2593818C/en not_active Expired - Fee Related
- 2005-01-19 RS RS20120436A patent/RS52513B/sr unknown
- 2005-01-19 EA EA200701267A patent/EA012164B1/ru not_active IP Right Cessation
- 2005-01-19 AU AU2005324536A patent/AU2005324536B2/en not_active Ceased
- 2005-01-19 JP JP2007551240A patent/JP4189026B2/ja not_active Expired - Fee Related
- 2005-01-19 MX MX2007008512A patent/MX2007008512A/es active IP Right Grant
- 2005-01-19 DK DK05723117.7T patent/DK1855705T3/da active
- 2005-01-19 ES ES05723117T patent/ES2391085T3/es not_active Expired - Lifetime
- 2005-01-19 NZ NZ556369A patent/NZ556369A/en not_active IP Right Cessation
- 2005-01-19 HR HRP20120809TT patent/HRP20120809T1/hr unknown
- 2005-01-19 CN CN2005800465258A patent/CN101098707B/zh not_active Expired - Fee Related
-
2007
- 2007-07-03 IL IL184376A patent/IL184376A0/en unknown
- 2007-07-05 NO NO20073491A patent/NO20073491L/no not_active Application Discontinuation
- 2007-07-11 TN TNP2007000262A patent/TNSN07262A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20073491L (no) | 2007-08-03 |
| EP1855705A4 (en) | 2008-11-12 |
| PL1855705T3 (pl) | 2012-12-31 |
| EP1855705B1 (en) | 2012-07-11 |
| NZ556369A (en) | 2009-08-28 |
| DK1855705T3 (da) | 2012-10-15 |
| AU2005324536A1 (en) | 2006-07-20 |
| EP1855705A1 (en) | 2007-11-21 |
| RS52513B (sr) | 2013-04-30 |
| EA200701267A1 (ru) | 2008-02-28 |
| JP4189026B2 (ja) | 2008-12-03 |
| ES2391085T3 (es) | 2012-11-21 |
| CA2593818A1 (en) | 2006-07-20 |
| CA2593818C (en) | 2014-12-16 |
| CN101098707B (zh) | 2011-11-30 |
| HRP20120809T1 (hr) | 2012-11-30 |
| MX2007008512A (es) | 2007-09-14 |
| AU2005324536B2 (en) | 2009-03-05 |
| TNSN07262A1 (fr) | 2008-12-31 |
| JP2008526961A (ja) | 2008-07-24 |
| IL184376A0 (en) | 2007-10-31 |
| SI1855705T1 (sl) | 2012-11-30 |
| EA012164B1 (ru) | 2009-08-28 |
| CN101098707A (zh) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Antimicrobial compounds from marine actinomycetes | |
| US20160263154A1 (en) | Compositions and methods for altering human cutaneous microbiome to increase growth of staphylococcus epidermidis and reduce staphylococcus aureus proliferation | |
| BRPI0412591A (pt) | antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e uso destes | |
| JP2012513467A5 (pt) | ||
| NO20073490L (no) | Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| CN105992814A (zh) | 组合物 | |
| Tyrrell et al. | The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii | |
| Giacometti et al. | In vitro activity and killing effect of the synthetic hybrid cecropin A–melittin peptide CA (1–7) M (2–9) NH2 on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics | |
| AR073917A1 (es) | Sinergismo antibiotico | |
| Oli et al. | Actinomycetes in medical and pharmaceutical industries | |
| US20190008875A1 (en) | Steroid alkaloids and compositions and kits thereof | |
| BRPI0519325A2 (pt) | compostos, complexo antibiàtico 107891, seus fatores a1 e a2, sais farmaceuticamente aceitÁveis, processo para produzir composiÇço e uso do mesmo | |
| US20140030242A1 (en) | Antifungal composition comprising polycyclic peptide compound and method for preparing the same | |
| UA87546C2 (ru) | Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли, композиция и их использование | |
| Farrell et al. | In vitro activity of lactone ketolide WCK 4873 when tested against contemporary community-acquired bacterial pneumonia pathogens from a global surveillance program | |
| Yehia et al. | Effect of linezolid alone and in combination with other antibiotics, on methicillin-resistant Staphylococcus aureus | |
| Michihara et al. | Polypeptides comprising arginine and lysine regulate the microbial balance in seborrheic dermatitis | |
| Sorlozano et al. | Activity of daptomycin against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae | |
| Nonpanya et al. | Synergistic antibacterial activities of bioactive compounds from Streptomyces sp. RS2 in combination with vancomycin against Staphylococcus aureus | |
| Aktas | Efficacy of Vancomycin with Fosfomycin against Vancomycin-Resistant Enterococcus Strains Using Agar Dilution Method. | |
| Ancuelo et al. | Potent Bioactivity of Bacteriocin-producing LAB Strains against Multi-drug-resistant Pathogens Isolated from Dairy Cattle with Clinical Mastitis. | |
| US20240041976A1 (en) | Composition and use | |
| Surve et al. | Toxicity of oxazolidinone linezolid on pathogenic microorganism Listeria ivanovii | |
| MY148891A (en) | Novel antibiotic, bispolides a1, a2 and a3, and process for poducing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NAICONS SCARL (IT) Free format text: TRANSFERIDO DE: VICURON PHARMACEUTICALS INC. |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: NAICONS SCARL (IT) Free format text: AFIM DE ATENDER AS DUAS TRANSFERENCIAS REQUERIDAS ATRAVES DA PETICAO NO 020100101258/RJ DE 28/10/2010, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE NOTARIZADO E COM A LEGALIZACAO CONSULAR, A GUIA RELATIVA A SEGUNDA TRANSFERENCIA SOLICITADA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25A | Requested transfer of rights approved |
Owner name: NEXTHERA BIOSCIENCES S.R.L. (IT) Free format text: TRANSFERIDO DE: NAICONS S.C.A.R.L. |
|
| B25A | Requested transfer of rights approved |
Owner name: SENTINELLA PHARMACEUTICALS, INC. (US) Free format text: TRANSFERIDO DE: NEXTHERA BIOSCIENCES S.R.L. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |